4 completed, 2 recruiting, 1 suspended. 5 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 3, Recruiting 1, Suspended 1 |
| Phase 1 | 1 | Completed 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow Khondrion BV: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| KHENERFIN Study: A Trial to Evaluate the Efficacy and Safety of Sonlicromanol in Primary Mitochondrial Diseases Sonlicromanol, Placebo - Mitochondrial Diseases, Maternally Inherited Diabetes and Deafness (MIDD) | Phase 3 | Recruiting | Khondrion BV | 220 | 2026-04-14 | 2026-10-14 |
| Sonlicromanol in Post-COVID Sonlicromanol, Placebo - Post COVID Condition | Phase 2 | Recruiting | Michele van Vugt | 80 | 2026-04-03 | 2026-08-18 |
| The KHENEREXT Study Oral administration of 100 mg KH176 twice daily - Mitochondrial Diseases, Mitochondrial DNA tRNALeu(UUR) m.3243A<G Mutation | Phase 2 | Completed | Khondrion BV | 11 | 2021-08-09 | 2024-03-06 |
| The KHENERGYC Study Sonlicromanol, Placebo - Mitochondrial Diseases, Mitochondrial DNA tRNALeu(UUR) m.3243A<G Mutation | Phase 2 | Suspended | Khondrion BV | 24 | 2021-02-01 | 2025-01-10 |
| The KHENERGYZE Study KH176, Placebo - Mitochondrial Diseases, Mitochondrial Myopathies | Phase 2 | Completed | Khondrion BV | 27 | 2019-10-30 | 2022-08-31 |
| The KHENERGY Study KH176, placebo - Mitochondrial Diseases, Mitochondrial Myopathies | Phase 2 | Completed | Khondrion BV | 20 | 2016-09-01 | 2018-02-23 |
| A Dose-escalating Clinical Trial With KH176 KH176, placebo - MELAS, LHON | Phase 1 | Completed | Khondrion BV | 32 | 2015-05-01 | 2021-10-18 |
MELAS Syndrome (6) · Mitochondrial Diseases (6) · Leigh Disease (2) · Mitochondrial Encephalomyopathies (2) · Mitochondrial Myopathies (2) · Noninsulin-dependent diabetes mellitus with deafness (2) · Ophthalmoplegia, Chronic Progressive External (1) · Post-Acute COVID-19 Syndrome (1)
6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid (4)
Netherlands (6) · Denmark (3) · Germany (3) · United Kingdom (3) · Belgium (1) · France (1) · Italy (1) · United States (1)
PMID 29037240, PMID 30058726, PMID 35477351
2025 (1)